ACTIVITY REPORT AND CASH FLOW REPORT
FOR THE QUARTER ENDED 30 SEPTEMBER 2024

Highlights:

- **Invion made significant progress in its clinical development program in the quarter.**
- **Release of successful Ph II prostate cancer results which demonstrated:**
  - **INV043 to be safe and well tolerated by patients with only mild side effects,**
  - **40% of patients had >30% reduction in lesion size (10% total regression) based on RECIST 1.1 framework,**
  - **44% of patients negative on PSMA-PET vs. 100% positive before treatment,**
  - **Final report concluded that "the favourable safety profile and the preliminary efficacy results are promising and warrant further investigation of INV043".**
- **Patient screening commenced this month in separate Ph I/II skin cancer trial after Invion was granted HREC approval from the St Vincent's Hospital and completed CTN filing.**
- **Invion has and will be presenting the trial findings and technology at several Australian and international biotech conferences.**

MELBOURNE (AUSTRALIA) 28 October 2024: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**") wishes to provide the following update and Appendix 4C for the quarter ended 30 September 2024 (**1QFY25**).

Summary of cash position and expenditure during the quarter

The Company held cash reserves at the end of the quarter of $1.2 million, compared with $784K for 4QFY24. Invion receives a monthly instalment of $100K a month, which maybe increased by mutual agreement to up to $500K/month, from New York-based investment manager, The Lind Partners (**Lind**), under a Share Purchase Agreement. This agreement runs to May 2025, unless extended.

The share placement to Lind is separate to and independent from the research and development (**R&D**) services agreement with RMW Cho Group (**RMW**), the licensor of the Photosoft™ technology.

Invion's key cash outflows under Operating Activities in the quarter were R&D costs of $506K and administration and corporate costs of $478k.

Operating cash outflow was higher than normal in the quarter as Invion made a number of one-off payments relating to the start of its Phase I/II non-melanoma skin cancer (**NMSC**) trial in Queensland (further details on the trial are highlighted below). As such, operating cash outflows are expected to decline in the current quarter.

As detailed in Item 6.1 of the accompanying Appendix 4C, the Company discloses that the aggregate payments to related parties and their associates during the quarter totalled $129K. The payment relates to CEO compensation and Directors fees paid in the period.

Key developments in the quarter

Invion made significant progress in its clinical development program in 1QFY25 for its lead drug candidate, INV043.

The Company reported promising results from a Phase II prostate cancer trial (ACTRN12621000633886) using a sublingual (under the tongue) formulation of INV043, the same active pharmaceutical ingredient (API) in the topical formulation that Invion is using for its Phase I/II NMSC trial.

The prostate cancer study used six treatment cycles of INV043 as a monotherapy. It was found to be safe and well tolerated by patients with no serious adverse events experienced and all side effects reported were mild.

Importantly, there were encouraging efficacy signals as well with 40% of patients showing a positive response to the treatment, including 10% demonstrating complete regression as measured by the Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 framework – a standard way to measure the response of a tumour to treatment.

Further, 44% of patients had negative Prostate Specific Membrane Antigen – Positron Emission Tomography (PSMA-PET) results three months post treatment (all patients were positive before the treatment).

The report on the results collated by Scendea Limited (**Scendea**) concluded that "the favourable safety profile and the preliminary efficacy results are promising and warrant further investigation of INV043".

In a separate development, Invion was granted Human Research Ethics Committee (**HREC**) approval from the St Vincent's Hospital Melbourne and successfully filed a Clinical Trial Notification (**CTN**) application with the Therapeutic Goods Administration (**TGA**) to commence the Phase I/II NMSC trial in Queensland.

Patient screening is underway and the primary endpoints of this open label trial focus on safety and secondary/exploratory endpoints include dose optimisation and efficacy signals.

As an adaptive trial design, additional cohorts of patients may be added to evaluate other safety aspects of the treatment if required, as well as dose optimisation and efficacy endpoints. As such, the total number of patients can range between 18 and 174, and the number of treatment cycles and the length of the study can vary because of this.

Skin cancer is one of the world's most common cancers and NMSC makes up over 98% of all skin cancers[1] with the global treatment market expected to reach US$21.1 billion by 2032[2].

Commenting on the latest quarterly activities, Invion's Executive Chair and Chief Executive Officer, Thian Chew, said:

> "We still have more work to do, but we believe our technology has been significantly derisked following *the results from the successful Phase II prostate cancer study, which have given us greater confidence in our current NMSC trial.*
>
> *"This is an exciting time for Invion and we hope to show that INV043 can be efficacious in more than one type of cancer as this will further highlight the uniqueness and value of the technology."*

Invion has and will be participating in and/or presenting the Photosoft technology and the prostate cancer results at several local and international conferences. Some of these include Bio Asia – Taiwan, BioJapan, AusBioInvest 2024 in Melbourne and BIO Investor Forum in San Francisco.

[1] https://www.cancercouncil.com.au/skin-cancer/about-skin-cancer/
[2] https://www.fortunebusinessinsights.com/skin-cancer-treatment-market-102806

During the quarter, Melanie Leydin joined Invion's Board of Directors as a Non-Executive Director. She is the Company's Chief Financial Officer and a member of the Institute of Chartered Accountants, Fellow of the Governance Institute of Australia and is a Registered Company Auditor.

She replaced Robert Merriel who retired from the Board on 31 August 2024 after four years of service.

Investing & Financing activities

Invion recorded a $1.4 million cash inflow from Financing Activities relating to the investment from Lind, and did not record any cash movements from its Investing Activities in the quarter.

The Company believes that its cash position, expected reduction in operating cash outflow, funding agreements and collaboration partnerships will enable it to pursue its current development agenda.

This announcement was approved for release by the Board of Directors.

***Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions**: https://investors.inviongroup.com/*

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea to the Photosoft™ technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX). For more information, visit www.inviongroup.com.

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side

effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity	
INVION LTD	
ABN	**Quarter ended ("current quarter")**
76 094 730 417	30 September 2024

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	-	-
1.2	Payments for		
	(a) research and development	(506)	(506)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs	-	-
	(f) administration and corporate costs	(478)	(478)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	-	-
1.5	Interest and other costs of finance paid	-	-
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	-	-
1.9	**Net cash from / (used in) operating activities**	**(984)**	**(984)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant, and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,500	1,500
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(98)	(98)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	**Net cash from / (used in) financing activities**	**1,402**	**1,402**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	784	784
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(984)	(984)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,402	1,402
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	**Cash and cash equivalents at end of period**	**1,202**	**1,202**

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	1,202	784
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**1,202**	**784**

6.	Payments to related parties of the entity and their associates	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	129
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(984)
8.2	Cash and cash equivalents at quarter end (item 4.6)	1,202
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	1,202
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	1.22

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Invion anticipates a reduction in operating cash outflow in the current quarter compared to the last quarter (1QFY25) when it made a number of one-off payments related to the commencement of its Phase I/II clinical trial in Queensland.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Yes. As announced on ASX on 28 June 2024, the Company has secured a minimum of $2.4m and up to $6.8m investment by US institutional investor, The Lind Partners. Under the agreement Invion will receive a monthly investment of $100,000, which may be increased to $500,000 on mutual agreement, until May 2025.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Yes, the Company expects to be able to continue its operations and meet its business objectives based on the answer to question 2 above.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 28 October 2024

Authorised by: By the Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.